These authors contributed equally to this work.
Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations
This article is protected by copyright. All rights reserved.
Neuropathology and Applied Neurobiology
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/nan.12057
- Accepted manuscript online: 10 MAY 2013 05:24AM EST
- Manuscript Accepted: 30 APR 2013
- Cited By
- action myoclonus;
- brown pigment;
- cerebellar cortex;
- cerebral cortex;
- progressive myoclonus epilepsy;
Mutations in the SCABR2 gene cause a rare autosomal recessive disease, progressive myoclonus epilepsy (PME) with or without renal failure, the former also being designated action myoclonus-renal failure syndrome. Although reported cases have been accumulating, only a few have described its neuropathology. We studied two Japanese patients with PME without renal failure, in whom the ages at onset and disease durations were 45 and 20 years, and 14 and 8.5 years, respectively.
Sequencing and restriction analysis of the SCARB2 gene and neuropathological examination with immunohistochemistry were performed.
Gene analyses revealed novel homozygous frame-shift and nonsense mutations in the SCARB2 gene. Both cases exhibited deposition of brown pigment in the brain, especially the cerebellar and cerebral cortices. Ultrastructurally, the pigment granules were localized in astrocytes. Neuronal loss and gliosis were also evident in the brain, including the pallido-luysian and cerebello-olivary systems. The spinal cord was also affected. Such changes were less severe in one patient with late-onset disease than in the other patient with early-onset disease. In brain and kidney sections, immunostaining with an antibody against the C-terminus of human SCARB2 revealed decreased levels and no expression of the protein, respectively.
The frame-shift mutation detected in the patient with late-onset disease is a hitherto undescribed, unique type of SCABR2 gene mutation. The present two patients are the first reported to have clearly demonstrated both extraneuronal brown pigment deposition and system neurodegeneration as neuropathologic features of PME with SCABR2 mutations.